Patent for coronavirus drug issued in Uzbekistan
30/06/2022 20:20
Patent for coronavirus drug issued in Uzbekistan
30/06/2022 20:20
Tashkent, Uzbekistan (UzDaily.com) -- Through the joint efforts of pharmacists and pharmacologists of this institute, based on natural and mineral sources, the multicomponent drug Anticovir was created by biotechnological and chemical synthesis.
Clinical and preclinical studies have shown that the drug prevents the penetration of coronavirus into cells with their subsequent damage and has an immunomodulatory effect aimed at increasing humoral immunity.
The components of the drug have anticoagulant, antioxidant, cytoprotective, immunomodulatory effects, as well as provide antibacterial and antiviral activity. Clinical studies indicate a high efficacy of the drug in 92 percent of patients, and no undesirable side effects were noted in the study group.
On 13 November 2020, the trademark of the drug was registered by the Intellectual Property Agency. On 14 February 2022, Antikovir was registered by the Ministry of Health as an antiviral drug recommended for the treatment and prevention of coronavirus infection and post-COVID syndrome.
$ 1 | 12570.00 | +0.024% |
1 | 13698.79 | -0.378% |
₽ 1 | 136.91 | -0.270% |